[
  {
    "ts": null,
    "headline": "Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays began coverage of AbbVie Inc. (NYSE:ABBV) with an Overweight rating. It set a price target of $275 on the stock. The firm said current consensus estimates do not fully reflect AbbVie’s operating leverage potential. In […]",
    "url": "https://finnhub.io/api/news?id=6fd2c5906be866ea01c421d956f6d334b0fe11b91bc1a67b9d4485f44119d20c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771870428,
      "headline": "Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential",
      "id": 139187258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays began coverage of AbbVie Inc. (NYSE:ABBV) with an Overweight rating. It set a price target of $275 on the stock. The firm said current consensus estimates do not fully reflect AbbVie’s operating leverage potential. In […]",
      "url": "https://finnhub.io/api/news?id=6fd2c5906be866ea01c421d956f6d334b0fe11b91bc1a67b9d4485f44119d20c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to invest $380 million to expand US manufacturing in Illinois",
    "summary": "Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic",
    "url": "https://finnhub.io/api/news?id=13cf841020c08fa999ff251de67484a837c0514fd29250ba06a4c0b2206a10e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771866577,
      "headline": "AbbVie to invest $380 million to expand US manufacturing in Illinois",
      "id": 139186389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic",
      "url": "https://finnhub.io/api/news?id=13cf841020c08fa999ff251de67484a837c0514fd29250ba06a4c0b2206a10e8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie plans to spend $380 million building two new manufacuturing facilities in North Chicago",
    "summary": "Biopharmaceutical company AbbVie plans to spend $380 million building two new manufacturing facilities in North Chicago – a rare example of a project that’s in line with initiatives by the administrations of Gov. JB Pritzker and President Donald Trump. The two plants are expected to create 300 new jobs, including positions for engineers, scientists, manufacturing operators and lab technicians, ...",
    "url": "https://finnhub.io/api/news?id=72c99604ceb6fb0f75b886b88128b1c94153a659db7e4640f2f31955fa80e7e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771862400,
      "headline": "AbbVie plans to spend $380 million building two new manufacuturing facilities in North Chicago",
      "id": 139186391,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company AbbVie plans to spend $380 million building two new manufacturing facilities in North Chicago – a rare example of a project that’s in line with initiatives by the administrations of Gov. JB Pritzker and President Donald Trump. The two plants are expected to create 300 new jobs, including positions for engineers, scientists, manufacturing operators and lab technicians, ...",
      "url": "https://finnhub.io/api/news?id=72c99604ceb6fb0f75b886b88128b1c94153a659db7e4640f2f31955fa80e7e9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States",
    "summary": "AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.",
    "url": "https://finnhub.io/api/news?id=ed2ddc5f71dbc143467ade04e44357d1d9d1c6af8fdcd2d2c361df2d2c0aebef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771862400,
      "headline": "AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States",
      "id": 139186390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.",
      "url": "https://finnhub.io/api/news?id=ed2ddc5f71dbc143467ade04e44357d1d9d1c6af8fdcd2d2c361df2d2c0aebef"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?",
    "summary": "ANIP gears up for Q4 earnings as Cortrophin Gel sales are expected to have surged, with rare disease momentum building despite generic competition pressures.",
    "url": "https://finnhub.io/api/news?id=d2390a52b95a2d894879f46f3f3ad1d23707668ba0a272b47aa80f21fc5be0f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771860900,
      "headline": "Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?",
      "id": 139186392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ANIP gears up for Q4 earnings as Cortrophin Gel sales are expected to have surged, with rare disease momentum building despite generic competition pressures.",
      "url": "https://finnhub.io/api/news?id=d2390a52b95a2d894879f46f3f3ad1d23707668ba0a272b47aa80f21fc5be0f2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs",
    "summary": "JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.",
    "url": "https://finnhub.io/api/news?id=299a1f5028806d5b568bfe15d2c4117b1d688b24e4e7f176ecb8064baf34145f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771852380,
      "headline": "Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs",
      "id": 139185148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.",
      "url": "https://finnhub.io/api/news?id=299a1f5028806d5b568bfe15d2c4117b1d688b24e4e7f176ecb8064baf34145f"
    }
  },
  {
    "ts": null,
    "headline": "Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather",
    "summary": "It’s been a fantastic 2026 for most dividend stocks so far this year, but most dividend-payers took a break last week. The Schwab U.S. Dividend Equity ETF was flat while the Consumer Staples SPDR fell 1.8%. With the stock market opening in about 90 minutes for the week, let’s take a look back at which ... Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather",
    "url": "https://finnhub.io/api/news?id=5f2a0a69dc4630b83d7aa3f9f50d329039d83527675357395a6d880cdead7bc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771851765,
      "headline": "Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather",
      "id": 139185163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "It’s been a fantastic 2026 for most dividend stocks so far this year, but most dividend-payers took a break last week. The Schwab U.S. Dividend Equity ETF was flat while the Consumer Staples SPDR fell 1.8%. With the stock market opening in about 90 minutes for the week, let’s take a look back at which ... Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather",
      "url": "https://finnhub.io/api/news?id=5f2a0a69dc4630b83d7aa3f9f50d329039d83527675357395a6d880cdead7bc6"
    }
  },
  {
    "ts": null,
    "headline": "Want To Simplify Investing? Buy These 2 ETFs And Let America Do The Work",
    "summary": "Want To Simplify Investing? Buy These 2 ETFs And Let America Do The Work",
    "url": "https://finnhub.io/api/news?id=b7a28989642cbd960fa9f14fefb6b132f0bd3469d962e5e9d167e36da8d19bd7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771849843,
      "headline": "Want To Simplify Investing? Buy These 2 ETFs And Let America Do The Work",
      "id": 139186091,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b7a28989642cbd960fa9f14fefb6b132f0bd3469d962e5e9d167e36da8d19bd7"
    }
  },
  {
    "ts": null,
    "headline": "IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer",
    "summary": "IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross into the newly created role of Chief Development Officer. In this role, Dr. Ross will be responsible for leading early clinical development for IDEAYA's emerging oncology pipeline and play a crucial role in guiding the company's long-term R&D strategy. Dr. Ross joins IDEAYA from AbbVie, where she served as Vice President, Head of Early Oncology R&D a",
    "url": "https://finnhub.io/api/news?id=d465935510c5724a85058248a69481a3d825eef98684e6605429b4efc0f5ecb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771844400,
      "headline": "IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer",
      "id": 139183033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross into the newly created role of Chief Development Officer. In this role, Dr. Ross will be responsible for leading early clinical development for IDEAYA's emerging oncology pipeline and play a crucial role in guiding the company's long-term R&D strategy. Dr. Ross joins IDEAYA from AbbVie, where she served as Vice President, Head of Early Oncology R&D a",
      "url": "https://finnhub.io/api/news?id=d465935510c5724a85058248a69481a3d825eef98684e6605429b4efc0f5ecb4"
    }
  },
  {
    "ts": null,
    "headline": "AI robots may outnumber workers in a few decades, ex-Citi executive says",
    "summary": "\"You can already buy a humanoid today, which gives you a payback period versus human workers of less than 10 weeks,\" a former Citi executive told CNBC.",
    "url": "https://finnhub.io/api/news?id=01f005f26bdcdb5f07a1653c7a93af143bfbc8316c4b72a9f6a0930d69c6f5b1",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771838795,
      "headline": "AI robots may outnumber workers in a few decades, ex-Citi executive says",
      "id": 139185748,
      "image": "https://image.cnbcfm.com/api/v1/image/108268350-1771845475923-gettyimages-2234632757-14_robot_laptop.jpeg?v=1771845491&w=1920&h=1080",
      "related": "ABBV",
      "source": "CNBC",
      "summary": "\"You can already buy a humanoid today, which gives you a payback period versus human workers of less than 10 weeks,\" a former Citi executive told CNBC. ",
      "url": "https://finnhub.io/api/news?id=01f005f26bdcdb5f07a1653c7a93af143bfbc8316c4b72a9f6a0930d69c6f5b1"
    }
  },
  {
    "ts": null,
    "headline": "1 Cash-Producing Stock to Target This Week and 2 We Ignore",
    "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
    "url": "https://finnhub.io/api/news?id=5b474631ff49361b4edd868d86d86957d905cfbf4fb8ce1b1ff9952511c6dfe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771821915,
      "headline": "1 Cash-Producing Stock to Target This Week and 2 We Ignore",
      "id": 139185164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
      "url": "https://finnhub.io/api/news?id=5b474631ff49361b4edd868d86d86957d905cfbf4fb8ce1b1ff9952511c6dfe5"
    }
  }
]